BACKGROUND: The rising incidence and histological change to adenocarcinoma in esophageal cancer over the past four decades has been among the most dramatic changes ever observed in human cancer. Recent reports have suggested that its increasing incidence may have plateaued over the past decade. Our aim was to examine the latest overall and stage-specific trends in the incidence of esophageal adenocarcinoma. PATIENTS AND METHODS: We used the Surveillance Epidemiology and End Results (SEER) database of the National Cancer Institute to identify all patients with adenocarcinoma of the esophagus and gastric cardia between 1973 and 2009. Both overall and stage-specific trends in incidence were analyzed using joinpoint regression analysis. RESULTS: The overall incidence of adenocarcinoma of the esophagus and the gastric cardia increased from 13.4 per million in 1973 to 51.4 per million in 2009, a nearly 400 % increase. Jointpoint analysis demonstrated that the yearly increase in incidence has slowed somewhat from 1.27 per million before 1987 to 0.97 between 1987 and 1997 and 0.65 after 1997. Stage-specific analysis suggests that the incidence of noninvasive cancer has actually declined after 2003 with a yearly decrease of 0.22. The percentage of patients diagnosed with in situ cancer declined after 2000 and remained under 2.5 % through the study period. CONCLUSIONS: The incidence of esophageal adenocarcinoma continues to rise in the USA. The percentage of patients diagnosed with in situ cancer has declined in the twenty-first century.
BACKGROUND: The rising incidence and histological change to adenocarcinoma in esophageal cancer over the past four decades has been among the most dramatic changes ever observed in humancancer. Recent reports have suggested that its increasing incidence may have plateaued over the past decade. Our aim was to examine the latest overall and stage-specific trends in the incidence of esophageal adenocarcinoma. PATIENTS AND METHODS: We used the Surveillance Epidemiology and End Results (SEER) database of the National Cancer Institute to identify all patients with adenocarcinoma of the esophagus and gastric cardia between 1973 and 2009. Both overall and stage-specific trends in incidence were analyzed using joinpoint regression analysis. RESULTS: The overall incidence of adenocarcinoma of the esophagus and the gastric cardia increased from 13.4 per million in 1973 to 51.4 per million in 2009, a nearly 400 % increase. Jointpoint analysis demonstrated that the yearly increase in incidence has slowed somewhat from 1.27 per million before 1987 to 0.97 between 1987 and 1997 and 0.65 after 1997. Stage-specific analysis suggests that the incidence of noninvasive cancer has actually declined after 2003 with a yearly decrease of 0.22. The percentage of patients diagnosed with in situ cancer declined after 2000 and remained under 2.5 % through the study period. CONCLUSIONS: The incidence of esophageal adenocarcinoma continues to rise in the USA. The percentage of patients diagnosed with in situ cancer has declined in the twenty-first century.
Authors: M D Gammon; J B Schoenberg; H Ahsan; H A Risch; T L Vaughan; W H Chow; H Rotterdam; A B West; R Dubrow; J L Stanford; S T Mayne; D C Farrow; S Niwa; W J Blot; J F Fraumeni Journal: J Natl Cancer Inst Date: 1997-09-03 Impact factor: 13.506
Authors: Karen Chiam; Tingting Wang; David I Watson; George C Mayne; Tanya S Irvine; Tim Bright; Lorelle Smith; Imogen A White; Joanne M Bowen; Dorothy Keefe; Sarah K Thompson; Michael E Jones; Damian J Hussey Journal: J Gastrointest Surg Date: 2015-05-06 Impact factor: 3.452
Authors: Caitlin C Murphy; Y Claire Yang; Nicholas J Shaheen; Wayne L Hofstetter; Robert S Sandler Journal: Dis Esophagus Date: 2017-02-01 Impact factor: 3.429
Authors: Ali H Zaidi; Vanathi Gopalakrishnan; Pashtoon M Kasi; Xuemei Zeng; Usha Malhotra; Jeya Balasubramanian; Shyam Visweswaran; Mai Sun; Melanie S Flint; Jon M Davison; Brian L Hood; Thomas P Conrads; Jacques J Bergman; William L Bigbee; Blair A Jobe Journal: Cancer Date: 2014-08-05 Impact factor: 6.860
Authors: Deborah T Leicht; Tasneem Kausar; Zhuwen Wang; Daysha Ferrer-Torres; Thomas D Wang; Dafydd G Thomas; Jules Lin; Andrew C Chang; Lin Lin; David G Beer Journal: J Thorac Oncol Date: 2014-06 Impact factor: 15.609